Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study

Digestive and Liver Disease

Volumn 42, Issue 3, 2010, Pages 191-195

  Meucci, Gianmichele ^a   D'Incà, Renata ^c   Maieron, Roberto ^b   Orzes, Nicoletta ^e   Vecchi, Maurizio ^d   Visentini, Daniela ^b   Minoli, Giorgio ^a   Dal Pont, Elisabetta ^c   Zilli, Maurizio ^b   Benedetti, Elvio ^e   Virgilio, Tiziana ^d   Tonutti, Elio ^b  

^a VALDUCE HOSPITAL   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e Ospedale Civile di Gorizia   (Italy)

Author keywords

Calprotectin

Indexed keywords

CALGRANULIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DIARRHEA; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENTERITIS; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; PROTEIN FUNCTION;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; CONSTIPATION; DIARRHEA; FECES; FEMALE; GASTROENTERITIS; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; OUTPATIENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 76049109946     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.07.002     Document Type: Article

References (40)

1. Johne B., Fagerhol M.K., Lyberg T., et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 50 (1997) 113-123
2. Bjerke K., Halstensen T.S., Jahnsen F., et al. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 34 (1993) 1357-1363
3. Yui S., Mikami M., and Yamazaki M. Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. J Leukoc Biol 58 (1995) 650-658
4. Brun J.G., Ulvestad E., Fagerhol M.K., and Jonsson R. Effects of human calprotectin (L1) on in vitro immunoglobulin synthesis. Scand J Immunol 40 (1994) 675-680
5. Steinbakk M., Naess-Andresen C.F., Lingaas E., et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336 (1990) 763-765
6. Roseth A.G., Fagerhol M.K., Aadland E., and Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 27 (1992) 793-798
7. Roseth A.G., Schmidt P.N., and Fagerhol M.K. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 34 (1999) 50-54
8. Tibble J., Teahon K., Thjodleifsson B., et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 47 (2000) 506-513
9. Hanai H., Takeuchi K., Iida T., et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 49 (2004) 1438-1443
10. Langhorst J., Elsenbruch S., Mueller T., et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 11 (2005) 1085-1091
11. Canani R.B., Terrin G., Rapacciuolo L., et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 40 (2008) 547-553
12. Sipponen T., Savilahti E., Kolho K.L., et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 14 (2008) 40-46
13. D'Incà R., Dal Pont E., Di Leo V., et al. Can calprotectin predict relapse in inflammatory bowel disease?. Am J Gastroenterol 103 (2008) 2007-2014
14. Walkiewicz D., Werlin S.L., Fish D., et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 14 (2008) 669-673
15. Costa F., Mumolo M.G., Ceccarelli L., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54 (2005) 364-368
16. Orlando A., Modesto I., Castiglione F., et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci 10 (2006) 17-22
17. Tibble J.A., Sigthorsson G., Foster R., et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 45 (1999) 362-366
18. Larsen A., Hovdenak N., Karlsdottir A., et al. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. Scand J Gastroenterol 39 (2004) 1113-1118
19. Kristinsson J., Nygaard K., Aadland E., et al. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II. Digestion 64 (2001) 104-110
20. Tibble J., Sigthorsson G., Foster R., et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49 (2001) 402-408
21. Johne B., Kronborg O., Ton H.I., et al. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 36 (2001) 291-296
22. Kronborg O., Ugstad M., Fuglerud P., et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 46 (2000) 795-800
23. Roseth A.G., Kristinsson J., Fagerhol M.K., et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer?. Scand J Gastroenterol 28 (1993) 1073-1076
24. Costa F., Mumolo M.G., Bellini M., et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 35 (2003) 642-647
25. Summerton C.B., Longlands M.G., Wiener K., and Shreeve D.R. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 14 (2002) 841-845
26. Limburg P.J., Ahlquist D.A., Sandborn W.J., et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 95 (2000) 2831-2837
27. Tibble J.A., Sigthorsson G., Bridger S., et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119 (2000) 15-22
28. Dolwani S., Metzner M., Wassell J.J., et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 20 (2004) 615-621
29. Fagerberg U.L., Loof L., Myrdal U., et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 40 (2005) 450-455
30. Bremner A., Roked S., Robinson R., et al. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr 94 (2005) 1855-1858
31. D'Incà R., Dal Pont E., Di Leo V., et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 22 (2007) 429-437
32. Sutherland L.R., Martin F., Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92 (1987) 1894-1898
33. Mary J.Y., and Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30 (1989) 983-989
34. Vermeire S., Van Assche G., and Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 55 (2006) 426-431
35. Roseth A.G. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis 35 (2003) 607-609
36. Tibble J.A., Sigthorsson G., Foster R., et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 123 (2002) 450-460
37. Husebye E., Ton H., and Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 96 (2001) 2683-2687
38. Gilbert J.A., Ahlquist D.A., Mahoney D.W., et al. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol 31 (1996) 1001-1005
39. Hoff G., Grotmol T., Thiis-Evensen E., et al. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 53 (2004) 1329-1333
40. Limburg P.J., Devens M.E., Harrington J.J., et al. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 98 (2003) 2299-2305